Validation of the Decipher genomic classifier in patients receiving salvage radiotherapy without hormone therapy after radical prostatectomy - an ancillary study of the SAKK 09/10 randomized clinical trial. - Publication

Publication

Validation of the Decipher genomic classifier in patients receiving salvage radiotherapy without hormone therapy after radical prostatectomy - an ancillary study of the SAKK 09/10 randomized clinical trial.

Journal Paper/Review - May 28, 2022

Dal Pra Alan, Ghadjar Pirus, Hayoz S, Liu V Y T, Spratt D E, Thompson D J S, Davicioni E, Huang H-C, Zhao X, Liu Yali, Scharf Christop, Gut P, Plasswilm Ludwig, Hölscher Tobias, Polat Bülent, Hildebrandt G, Müller A-C, Pollack A, Thalmann G N, Zwahlen D, Aebersold D M

Citation

Dal Pra A, Ghadjar P, Hayoz S, Liu V, Spratt D, Thompson D, Davicioni E, Huang H, Zhao X, Liu Y, Scharf C, Gut P, Plasswilm L, Hölscher T, Polat B, Hildebrandt G, Müller A, Pollack A, Thalmann G, Zwahlen D, Aebersold D. Validation of the Decipher genomic classifier in patients receiving salvage radiotherapy without hormone therapy after radical prostatectomy - an ancillary study of the SAKK 09/10 randomized clinical trial. Ann Oncol 2022; 33:950-958.

Type

Journal Paper/Review (English)

Journal

Ann Oncol 2022; 33

Publication Date

May 28, 2022

Issn Electronic

1569-8041

Pages

950-958

Brief description/objective

The Decipher genomic classifier (GC) has shown to independently prognosticate outcomes in prostate cancer. The objective of this study was to validate the GC in a randomized phase III trial of dose-escalated salvage radiotherapy (SRT) after radical prostatectomy.